Who is sponsoring NCT07416734?

NCT07416734 is sponsored by University of California, San Francisco.

What drugs are being tested in NCT07416734?

Interventions in NCT07416734: HeartBot II Program, Waitlist Control.

What condition does NCT07416734 study?

NCT07416734 studies Participants Must be Women Aged 25 Years or Older, Participants Should Have no Self-reported History of Heart Disease or Stroke, Participants Should Have no Terminal Illness or Diagnosed Cognitive Impairment, Including Alzheimer's Disease, Participants Should Not be a Healthcare Professionals or Healthcare Trainees, Participants Should Not be Employed in the Healthcare Field, Participants Should Reside in the United States and be a University of California, San Francisco Health Patient, Participants Should Possess a Smartphone With an Active Data Plan or Access to Wi-Fi.

Is NCT07416734 still recruiting?

NCT07416734 is currently not yet recruiting. Last updated 18 February 2026.

Last reviewed 2026-02-18 · How we verify

NCT07416734: HeartBot II

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

RCT of HeartBot in Women

Not yet recruiting NA Last updated 18 February 2026

What this trial tests

NA trial testing HeartBot II Program in Participants Must be Women Aged 25 Years or Older in 200 participants. Not yet recruiting.

Timeline

1 March 2026

Primary endpoint
30 June 2027

30 June 2027

Quick facts

Lead sponsor	University of California, San Francisco
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	200
Start date	1 March 2026
Primary completion	30 June 2027
Estimated completion	30 June 2027
Sites	1 location across United States

Drugs / interventions tested

HeartBot II Program
Waitlist Control

Conditions studied

Participants Must be Women Aged 25 Years or Older — all drugs for Participants Must be Women Aged 25 Years or Older →
Participants Should Have no Self-reported History of Heart Disease or Stroke — all drugs for Participants Should Have no Self-reported History of Heart Disease or Stroke →
Participants Should Have no Terminal Illness or Diagnosed Cognitive Impairment, Including Alzheimer's Disease — all drugs for Participants Should Have no Terminal Illness or Diagnosed Cognitive Impairment, Including Alzheimer's Disease →
Participants Should Not be a Healthcare Professionals or Healthcare Trainees — all drugs for Participants Should Not be a Healthcare Professionals or Healthcare Trainees →

Sponsor

University of California, San Francisco

Who can join

25 and older, female only, with Participants Must be Women Aged 25 Years or Older or Participants Should Have no Self-reported History of Heart Disease or Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to find out whether an app-based program called HeartBot II, which uses an artificial intelligence (AI) chatbot, can help improve women's awareness and knowledge of heart attacks in women. This is an online study with about 200 women taking part. Participants will be randomly assigned (by chance) to one of two groups: an intervention group or a wait-list control group. Participants in the intervention group will begin using the HeartBot II program right away. Participants in the wait-list control group will wait 12 weeks before starting the HeartBot II program. The HeartBot II program includes four short modules. In each module, participants will interact with a chatbot and spend about 10 to 15 minutes completing the content. Participants will be asked to complete an online screening and baseline survey at the start of the study, as well as two follow-up surveys at 12 weeks and 24 weeks.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University of California, San Francisco trials

Trials by the same sponsor.

NCT05284773 — Screening for Acute Malnutrition · NA · withdrawn
NCT04634851 — Video Home Visits for Dietary Counselling · NA · not yet recruiting
NCT06065670 — Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a M · Phase 1, PHASE2 · not yet recruiting
NCT07534098 — Intervention for Hearing Health Among Native Americans · NA · not yet recruiting
NCT06960421 — Exercise-based Frailty Intervention in Lung Transplantation (XFIT) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07416734 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, San Francisco
Last refreshed: 18 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07416734.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing